Download PDF

Other users also viewed these articles

Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis Jesús Tornero-Molina; Mercedes Alperi-López; Ivan Castellví; Juan José de Agustín-de Oro; Alejandro Escudero; Rosario García-Vicuña; Miguel Ángel González-Gay; Cristina Hidalgo; Esteban Rubio; Raimon Sanmartí; Núria Casamira; Jaime Calvo-Alén;
Reumatol Clin. 2022;18:33-41
Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure Francisco J. Blanco; Esteban Rubio-Romero; Raimon Sanmartí; César Díaz-Torné; Pablo Talavera; Jochen Dunkel; Esperanza Naredo;
Reumatol Clin. 2020;16P1:345-52
Efficacy and safety of combined therapy with synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: Systematic literature review Jaime Calvo Alén; Trinidad Pérez; Susana Romero Yuste; Iván Ferraz-Amaro; Juan José Alegre Sancho; José Antonio Pinto Tasende; Francisco Maceiras Pan; Juan Carlos Quevedo; M. Vanesa Hernández-Hernández; Cristina Hidalgo Calleja; Alejandro San Martín Álvarez; María Isabel Tevar Sánchez; Raimon Sanmartí;
Reumatol Clin. 2020;16P1:324-32